De Mey Jo G R, Megens Remco, Fazzi Gregorio E
Department of Pharmacology and Toxicology, Universiteit Maastricht, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
J Pharmacol Exp Ther. 2008 Mar;324(3):930-7. doi: 10.1124/jpet.107.133660. Epub 2007 Nov 30.
To test the hypothesis that endogenous neuropeptide Y (NPY) counteracts the vasodilator effects of calcitonin gene-related peptide (CGRP), we used isolated mesenteric resistance arteries of rats and mice. With immunohistochemistry, we observed CGRP-containing fibers along and in the vicinity of a subset of NPY- or tyrosine hydroxylase-immunoreactive fibers. The CGRP1 receptor component calcitonin-related-like receptor was expressed by periarterial nerves and smooth muscle cells, whereas receptor activity-modifying protein 1 was observed primarily on the smooth muscle. In organ chambers, exogenous CGRP caused relaxations that were reversed by exogenous NPY. The effects were inhibited by 1-piperidinecarboxamide, N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]-carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)-methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS, a CGRP1 receptor antagonist; pK(B) = 8.54 +/- 0.52) and (R)-NZ-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]argininamide (BIBP3226, a Y1 antagonist; pK(B) = 7.00 +/- 0.49), respectively. Pretreatment with capsaicin (1 muM; 20 min) and the presence of BIBN4096BS (20 nM) increased contractile responses to K(+) (20-40 mM) and electrical field stimulation (EFS; 1-32 Hz). NPY increased contractile responses to K(+) and BIBP3226 (400 nM) reduced contractile responses to EFS. These effects were inhibited by capsaicin and BIBN4096BS, respectively. Furthermore, the relaxing effect of exogenous CGRP (10 nM) during phenylephrine-induced contraction (30 muM) was reversed by EFS, and this effect was reduced in the presence of BIBP3226. We confirmed that bioactive concentrations of endogenous CGRP and NPY can be released from periarterial sensory-motor and sympathetic nerves, respectively, and we demonstrate for the first time functional antagonism between endogenous NPY and CGRP at the level of the smooth muscle.
为了验证内源性神经肽Y(NPY)可抵消降钙素基因相关肽(CGRP)的血管舒张作用这一假说,我们使用了大鼠和小鼠的离体肠系膜阻力动脉。通过免疫组织化学方法,我们观察到在一部分NPY或酪氨酸羟化酶免疫反应阳性纤维及其附近有含CGRP的纤维。CGRP1受体成分降钙素相关样受体由动脉周围神经和平滑肌细胞表达,而受体活性修饰蛋白1主要在平滑肌上观察到。在器官浴槽中,外源性CGRP引起的舒张反应被外源性NPY逆转。这些效应分别被1-哌啶甲酰胺、N-[2-[[5-氨基-1-[[4-(4-吡啶基)-1-哌嗪基]羰基]戊基]氨基]-1-[(3,5-二溴-4-羟基苯基)甲基]-2-氧代乙基]-4-(1,4-二氢-2-氧代-3(2H)-喹唑啉基)(BIBN4096BS,一种CGRP1受体拮抗剂;pK(B)=8.54±0.52)和(R)-NZ-(二苯基乙酰基)-N-[(4-羟基苯基)甲基]精氨酰胺(BIBP3226,一种Y1拮抗剂;pK(B)=7.00±0.49)抑制。用辣椒素(1μM;20分钟)预处理以及存在BIBN4096BS(20 nM)可增加对K⁺(20 - 40 mM)和电场刺激(EFS;1 - 32 Hz)的收缩反应。NPY增加对K⁺的收缩反应,而BIBP3226(400 nM)降低对EFS的收缩反应。这些效应分别被辣椒素和BIBN4096BS抑制。此外,在去氧肾上腺素诱导的收缩(30μM)过程中,外源性CGRP(10 nM)的舒张作用被EFS逆转,并且在存在BIBP3226的情况下这种作用减弱。我们证实内源性CGRP和NPY的生物活性浓度可分别从动脉周围感觉运动神经和交感神经释放,并且我们首次证明了内源性NPY和CGRP在平滑肌水平上的功能拮抗作用。